Targeting cancer stem cells in drug discovery: Current state and future perspectives

doi:10.4252/wjsc.v11.i7.398

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 7

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (14110)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-5) series, Tables (1-3) series.

Item

Count

PDF

1187

WORD

430

HTML

9243

Figures (1-5)

204

Tables (1-3)

211

Sum=11275

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

285

Download

561

Sum=846

Publishing Process of This Article

Item

Count

Browse

744

Download

1245

Sum=1989

Jul 26, 2019 (publication date) through Jul 3, 2024

Times Cited of This Article

Times Cited (67)

Journal Information of This Article

Publication Name

World Journal of Stem Cells

ISSN

1948-0210

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Stem Cells. Jul 26, 2019; 11(7): 398-420
Published online Jul 26, 2019. doi: 10.4252/wjsc.v11.i7.398

Table 1 Agents targeting the Wnt signaling pathway in clinical trials

Compound	Target/mechanism	Tumor type	Highest phase	Organization
LGK974[53]	Porcupine inhibitor	Melanoma; breast cancer; pancreatic cancer	Phase I	Novartis
ETC-159[54]	Porcupine inhibitor	Solid tumors	Phase I	ETC/Duke-NUS
PRI-724[55]	β-catenin/CBP	Myeloid leukemia	Phase I/II	Prism/Eisai Pharmaceuticals
XAV939[59]	Tankyrase 1 and 2 inhibitor	-	Preclinical	Novartis
IWR1[61]	Tankyrase 1 and 2 inhibitor	-	Preclinical	Tocris Bioscience
JW74[70]	Tankyrase 1 and 2 inhibitor	-	Preclinical	Tocris Bioscience
NSC668036[71]	Disheveled	-	Preclinical	Tocris Bioscience
OMP-18R5[64] (Vantictumab)	Frizzled receptor	Solid tumors; breast cancer; non-small cell lung cancer; pancreatic cancer	Phase I/Ib	OncoMed Pharmaceuticals
OMP-54F28[65] (Ipafricept)	Fzd8-Fc fusion protein	Solid tumors; hepatocellular carcinoma; ovarian cancer; pancreatic cancer	Phase I/Ib	OncoMed Pharmaceuticals

Citation: Du FY, Zhou QF, Sun WJ, Chen GL. Targeting cancer stem cells in drug discovery: Current state and future perspectives. World J Stem Cells 2019; 11(7): 398-420
URL: https://www.wjgnet.com/1948-0210/full/v11/i7/398.htm
DOI: https://dx.doi.org/10.4252/wjsc.v11.i7.398